| pubmed-article:10638632 | pubmed:abstractText | Based on correlations between potencies of various dopamine D2/D3 agonists to substitute for the 7-OH-DPAT discriminative cue and their in vitro (mitogenesis test) potencies, it has been suggested that the 7-OH-DPAT cue is mediated by activity at the D3 subtype. We sought to verify that the 7-OH-DPAT cue could be blocked by PNU-99194A, a commercially available preferential D3 antagonist. Rats were trained (FR10 two-lever, food-reinforced schedule) to press one lever following 7-OH-DPAT (0.1 mg/kg i.p.) and the other lever following saline. Rats were then tested with various doses of 7-OH-DPAT alone or in combination with PNU-99194A. 7-OH-DPAT (0.003 to 0.3 mg/kg) engendered dose-dependent substitution; PNU-99194A (1 to 10 mg/kg) failed to antagonize the cue induced by 0.1 mg/kg of 7-OH-DPAT and, at 10 mg/kg, given in combination with 0.003 to 0.1 mg/kg of 7-OH-DPAT, PNU-99194A markedly shifted the 7-OH-DPAT dose-effect curve to the left, i.e., potentiated the 7-OH-DPAT cue. If PNU-99194A is a preferential D3 antagonist, the present data do not confirm the previous hypothesis that the 7-OH-DPAT cue is mediated by the D3 subtype. | lld:pubmed |
